Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | KLK7 | P49862 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4140012 | 0.91 | RAB9A (0.58) | CYP3A4ALDH1A1CYP1A2CYP2C19HSD17B10 | |
| SCHEMBL18392739 | 0.89 | CYP3A4 (0.52) | CYP3A4ALDH1A1CYP1A2CYP2C19HSD17B10 | |
| SCHEMBL10881776 | 0.87 | NPC1 (0.62) | CYP3A4ALDH1A1CYP1A2CYP2C19HSD17B10 | |
| SCHEMBL3186208 | 0.85 | CYP3A4 (0.58) | CYP3A4ALDH1A1CYP1A2CYP2C19HSD17B10 | |
| SCHEMBL1744784 | 0.84 | SMN1; SMN2 (0.64) | CYP3A4ALDH1A1CYP1A2CYP2C19HSD17B10 | |
| SCHEMBL11985734 | 0.84 | CYP3A4 (0.57) | CYP3A4ALDH1A1CYP1A2CYP2C19HSD17B10 | |
| SCHEMBL11259822 | 0.83 | CYP3A4 (0.56) | CYP3A4ALDH1A1CYP1A2CYP2C19HSD17B10 | |
| SCHEMBL29067230 | 0.83 | CYP3A4 (0.64) | CYP3A4ALDH1A1CYP1A2CYP2C19HSD17B10 | |
| SCHEMBL12341995 | 0.81 | CYP3A4 (0.53) | CYP3A4ALDH1A1CYP1A2CYP2C19HSD17B10 | |
| SCHEMBL14745413 | 0.81 | CYP3A4 (0.53) | CYP3A4ALDH1A1CYP1A2CYP2C19HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12458624-B2 | Deuterium-enriched substituted phenoxyphenyl acetic acids and acylsulfonamides | DHANOA DALJIT SINGH (US) | 2025-11-04 | — | — | US | disclosed |
| US-20240228491-A1 | METHIONINE ADENOSYLTRANSFERASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SCINNOHUB PHARMACEUTICAL CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| US-20230039319-A1 | DEUTERIUM-ENRICHED SUBSTITUTED PHENOXYPHENYL ACETIC ACIDS AND ACYLSULFONAMIDES | DHANOA DALJIT SINGH (US) | 2023-02-09 | — | — | US | disclosed |
| WO-2021118826-A1 | DEUTERIUM-ENRICHED SUBSTITUTED PHENOXYPHENYL ACETIC ACIDS AND ACYLSULFONAMIDES | DHANOA DALJIT (US) | 2021-06-17 | — | — | WO | disclosed |
| WO-2021118826-A1 | DEUTERIUM-ENRICHED SUBSTITUTED PHENOXYPHENYL ACETIC ACIDS AND ACYLSULFONAMIDES | DHANOA DALJIT (US) | 2021-06-17 | — | — | WO | disclosed |
| US-6207686-B1 | FOR THERAPY OF HYPERTENSION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-03-27 | — | — | US | disclosed |
| EP-0792265-A1 | ENDOTHELIN ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-09-03 | — | — | EP | disclosed |
| WO-1996015109-A1 | ENDOTHELIN ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-05-23 | — | — | WO | disclosed |
| US-4493823-A | USING CARBOXYBENZENE COMPOUND | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1985-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039319-A1 | DEUTERIUM-ENRICHED SUBSTITUTED PHENOXYPHENYL ACETIC ACIDS AND ACYLSULFONAMIDES | AGTR2, AGTR1, EDNRA | CYP3A4 2346/4885ALDH1A1 2247/4885CYP1A2 1388/4885 |
| US-12458624-B2 | Deuterium-enriched substituted phenoxyphenyl acetic acids and acylsulfonamides | AGTR2, AGTR1, EDNRA | CYP3A4 2346/4885ALDH1A1 2247/4885CYP1A2 1388/4885 |
| US-20240228491-A1 | METHIONINE ADENOSYLTRANSFERASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | MAT1A, AMD1, MAT2B | CYP3A4 391/4885ALDH1A1 118/4885CYP1A2 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.